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The purpose of the study was to test the therapeutic effects of novel vaccines for reducing weight gain and
increasing weight loss in diet induced obesity (DIO) model. Male C57BL/6 J mice, fed a 60% Kcal fat diet for
8 weeks prior to the start of the study, were vaccinated via the intraperitoneal route with two formulations (JH17 &
JH18) of chimeric-somatostatin vaccines at 1 and 22 days of the study. Control mice were injected with PBS. All
mice continued to be feed the 60% Kcal fat diet for the 6 week study. Body weights were measured two times a
week and food intake was measured weekly. At week 6, mice were euthanized and a terminal bleed was made and
antibody levels to somatostatin and levels of insulin-like growth factor 1 (IGF-1) were determined. Vaccination with
both vaccine formulations induced a statistically significant body weight change over the study period, as
compared with PBS controls. Percentage of baseline body weight was also significantly affected by vaccination
during the study period. Vaccinates finished the study at 104% and 107% of baseline weight, JH17 & JH18
respectively, while untreated controls reached 115% of baseline weight. Food intake per mouse was similar in all
mouse groups during the entire study. Control mice did not demonstrate any antibody titers to somatostatin, while
all vaccinated mice had measurable antibody responses (> 1:500,000 titer). IGF-1 levels were not statistically
significant among the groups, but were elevated in the JH18 vaccinates (mean 440.4 ng/mL) when compared with
PBS controls (mean 365.6 ng/mL). Vaccination with either JH17 or JH18 chimeric –somatostatin vaccines produced
a statistically significant weight loss as compared with PBS controls (P< 0.0001), even though the DIO mice with
continually fed a 60% Kcal fat diet. The weight loss/lower weight gain observations were even more significant, as
all mice consumed similar amounts of food for the entire study. The presence of high levels of anti-somatostatin
antibodies at 6 weeks was correlative with the weight observations and confirmed the success of vaccination.
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The prevalence of obesity has risen dramatically in the
past decade and is a very serious health problem in
the United States, United Kingdom and elsewhere in
the world. Obesity is a risk factor for high blood pres-
sure, heart disease, stroke, gall bladder disease, breast
cancer, prostate cancer, colon cancer, and type 2 dia-
betes [1,2]. As a result, extensive biopharmaceutical re-
search is focused upon identifying compounds that can
promote weight loss without adversely affecting other
aspects of physiology.
One method for pharmacological treatment of obesity
is to focus on energy metabolism: appetite and energyCorrespondence: keith.haffer@braaschbiotech.com
Braasch Biotech LLC, 421 Rose Avenue, Garretson, SD 570303-0430, USA
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reproduction in any medium, provided the orintake are both reduced while energy expenditure is
maximized. Target candidates for this treatment are
growth hormone (GH) and insulin-like growth factor 1
(IGF-1). The latter is secreted by the liver by stimulation
of GH and has specific metabolic effects [3]. Treatment
with exogenous GH has been reported to have positive
effects on obesity in multiple animal models of obesity
as well as in human clinical studies [4]. In rat models,
the effects of GH treatment accelerated loss of body fat,
reduced hypertension and improved cardiovascular func-
tion [5,6].
Somatostatin is a 14 amino acid, peptide hormone
produced in the hypothalamus as well as certain por-
tions of the digestive system. Somatostatin is known to
inhibit the release of GH from the anterior pituitary [7].
Immunization of animals to somatostatin has beenis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mal inhibitory effects and increasing levels of both GH
and IGF-1 [8,9]. Importantly, these somatostatin-based
immunization procedures avoid the direct use of ana-
bolic hormones, such as GH or IGF-1[10].
The purpose of the present study was to determine if
immunization with somatostatin vaccines in a polygenic,
diet-induced-obesity (DIO) mouse model was effective
in reducing weight gain and increasing weight loss. The
C57BL/6 J (BL) strain is the most commonly used refer-
ence strain for diabetes research [11]. The Jackson La-
boratory (Harbor, ME) has extensively characterized this
mouse strain as to typical weights, plasma glucose levels
and percent body fat when fed 10%, 45%, or 60% fat
diets [12].
The male C57BL/6 J (BL) mice were continuously
fed a 60% Kcal fat diet to test the efficacy of the vac-
cines without any other contributing factors. In this
way, any change in body composition or metabolism
could unequivocally be associated with immune re-
sponse control of somatostatin. We validated the ef-
fectiveness of the vaccines by terminal analysis of
mouse serum for the presence of antibodies to somato-
statin and IGF-1 levels.
Methods and procedures
Unless stated otherwise all chemicals used in this study
were obtained from Sigma Aldrich (St. Louis, MO). All
ELISA reagents were obtained from KPL (Gaithersburg,
MD). The DIO mouse studies were conducted at The
Jackson Laboratory West (Sacramento, CA).
Animals
Male C57BL 6 J 60% DIO mice were received from The
Jackson Laboratory (Bar Harbor, ME) at 10 weeks of age.
All mice were acclimated for 2 weeks and then assigned
to treatment groups based on body weights. The mice
were ear notched for identification using a standard
mouse ID format. Mice were housed at a density of 2–4
per cage in polycarbonate cages which were both indi-
vidually and positively ventilated. The study was con-
ducted according to an IACUC approved protocol and
in compliance with the Guide for the Care and use of
Laboratory Animals (National Research Council, 1996).
Filtered tap water acidified to a pH of 2.8 to 3.2 was pro-
vided ad libitum. High fat diet (D12492) was obtained
from Research Diets, Inc (New Brunswick, NJ) and was
fed ad libitum. Body weights were measured two times
per week for 6 weeks. Food intake was measured weekly.
Cage side observations were made daily. Mice were
euthanized by CO2 inhalation at the end of the study.
Terminal blood was collected by cardiac puncture and
collected into EDTA tubes. Blood was processed to
plasma and stored at −80 °C until sent for analysis.Vaccines and vaccinations
Vaccines were prepared from purified E. coli expressed
inclusion body containing chimeric-somatostatin pro-
tein, according to “Mendelsohn et al. [13].” Vaccines
were formulated with either JH17 or JH18 adjuvants
and contained 1 mg protein/mL [14]. The chimeric-
somatostatin vaccines will be referred to in the text as
simply JH17 and JH18. Vaccines were administered by
intraperitoneal injection at day 1 and day 22 of the
study. Control mice were vaccinated in a similar man-
ner with PBS. These vaccines had previously been
tested and approved for safety and efficacy in a non-
obese mouse model.
IGF-1 measurements
Individual plasma samples were measured with a com-
mercially available mouse/rat IGF-1 sandwich immuno-
assay ELISA Kit (DSL-10-29200, Diagnostic Systems
Laboratories, Inc., Webster, TX). The ELISA is specific
for IGF-1 and can detect levels as low as 2 ng/mL. A set
of mouse/rat IGF-1 standards were used to generate a
standard curve and plasma samples results were fitted
onto the standard curve to determine IGF-1 ng/mL. The
precision of the assay was reported as a mean coefficient
of variation percentage (CV %) and intra-assay CV% was
6.5 while the inter-assay CV% was 5.4.
Insulin assays
Individual plasma samples were measured with a com-
mercially available Mouse Insulin sandwich immuno-
assay ELISA Kit (ALPCO 80-INSMS-E01, “E10;” ALPCO
Diagnostics, Salem, NH). The ELISA is specific for
mouse insulin and the sensitivity of the assay is 0.06 ng/
mL. A set of mouse insulin standards were used to gener-
ate a standard curve and plasma samples results were fit-
ted onto the standard curve to determine insulin ng/mL.
The reported assay precisions were 3.7% (intra-assay)
and 3.2% (inter-assay).
Somatostatin antibody responses
Plasma IgG antibodies, specific for chimeric–somato-
statin were determined by an indirect sandwich ELISA.
Briefly, Maxisorp plates (Nalgene Nunc, Rochester, NY)
were coated with refolded chimeric-somatostatin protein
in 0.01 mol/L borate buffer. A 100 μL aliquot of the pro-
tein containing 40.5 ng was coated into each well of the
plate and allowed to incubate at 2 to 8 °C for 18 hours.
After incubation, the plates were emptied and washed
once with phosphate buffered saline (pH 7.2) containing
0.05% Tween 20 (PBS-T). All wells were then blocked
with 100μL of SIGMA Block and incubated at 37 °C for
1 hour. Plates were then emptied and washed three
times with PBS-T. Plasma was diluted from 1:200 to
1:1,600 in Sigma Block. Each dilution of Plasma was
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37 °C. A pool of negative mouse plasma, also at 1:200 to
1:1,600 dilutions, was included on each plate. Plates were
then emptied and washed three times with PBS-T. Goat
anti-mouse IgG-HRP was diluted to 1:2,000 dilution in
PBS-T and 100 μL was added to each well. Plates were
incubated for 1 hour at 37 °C. Plates were then emptied
and washed three times with PBS-T. Sureblue ™ HRP sub-
strate was added to each well in 100 μL volumes. Reactions
were allowed to run for 10 minutes and then stopped with
100 μL of TMB stop solution. Plates were air blanked then
read at 450 nm on an ELx800 Reader controlled by KC
Junior software (Bio-Tek, Winooski, VT). Linear regression
curves for each plasma sample were determined by Micro-
soft Excel software (Redmond, WA). Endpoint titers were
assigned a 0.2 OD and were interpolated from each regres-
sion curve for each mouse. The precision of the somato-
statin antibody assay was 3.8% and 5.3%, intra-assay and
inter-assay CV%, respectively.
Data analysis
The results are presented as mean ± SEM Comparisons
between groups for: body weight means; percent final
body weight vs. baseline weight; percent of baseline body
weight; and, IGF-1 were conducted using an unpaired
two-tailed t-test or one-tailed Mann –Whitney (Prism
Software; GraphPad San Diego, CA). A P value of <0.05
was considered significant. Regression line slope analysis
of cumulative food intake was also conducted with
Prism Software.
Results
Effect of somatostatin vaccines on body weight
parameters
Data in Figure 1 demonstrates the effects of vaccination
on the mean body weights by treatment group. The ori-
ginal vaccination regime was set at 0.5 mL administered
by intraperitoneal injection on days 1 and 22. The initial
loss of body weight was first observed at 4 days post- 1st
vaccination and was 12.2% and 13.1% for JH 17 and
JH18, respectively. Due to the large weight loss, and the
concern for the mouse health, the study directors
decided to reduce the second vaccination by 1/5th and
administer only 0.1 mL on day 22. This second vaccin-
ation resulted in an initial weight loss of 2.1% and 1.8%
during the 3 days post- 2nd vaccination, JH 17 and JH18
respectively. Statistical determinations of body weight
means between JH17 and PBS controls was highly statis-
tically significant by the unpaired two-tailed t-test (P
< 0.0001). The statistical determinations of JH18 versus
the PBS controls demonstrated the same statistical
significance (P< 0.0001). By study date 32, 10 days post-
2nd vaccination, both the JH17 and JH18 –vaccinated
mice returned to their day 1 baseline body weights, whilethe PBS controls had gained 4.1 g above their baseline
weights. At the end of the study (day 39), there was a
weight differential of 3.43 and 3.78 g between the PBS
controls and JH17 and JH18 vaccinates, respectively.
Data in Figure 2 demonstrates the effects of vaccin-
ation on the percent of baseline weights by treatment
group. This figure depicts baseline weights as 100%
and all other weight determinations are compared
with this baseline value. Similarly, highly statistical
differences were observed with both vaccine groups
versus the PBS controls (P< 0.0001). At day 39, the
mean percent baseline weights were 107.1%, 104.0%
and 115.5% for JH17 vaccinates, JH18 vaccinates and
PBS controls, respectively. The differences between
JH17 and JH18 vaccinates were not statistically sig-
nificant, although JH18 produced a noticeably lower
percent of baseline weight at all post-vaccination days
of the study.
Effect of somatostatin vaccines on food intake
Data in Figure 3 depicts the cumulative food intake
of treatment groups during the study. Values are for
each 10 mouse treatment group. Although there was
a significant drop in cumulative food consumption for
the first 2 days of the study in JH17 and JH18 vacci-
nates, associated with post-adjuvant injection stress,
weekly food consumption through the end of the
study was consistent with the PBS control group. Ad-
juvant controls were not included in this study as no
negative effect had previously been observed. At
study’s end, the cumulative food intake was 105.2 g
for JH17, 99.6 g for JH18 and 113.8 g for PBS con-
trols. Based upon the unpaired t-tests and regression
slope analyses, there were not statistically significant
differences between either the JH17 or JH 18 mice
and the PBS control mice.
Antibody responses to chimeric-somatostatin vaccine
antigen
Data in Figure 4 demonstrates the immune response
after two vaccinations with chimeric-somatostatin pro-
tein by ELISA endpoint titers. The PBS controls had no
demonstrable titers to somatostatin at the 1:200 initial
dilution and were assigned a baseline value of 2 log10
(< 1:200 dilution). JH 17 vaccinates mounted a mean
ELISA titer of 4.6 log10 and the titers for JH18 vacci-
nated mice was 4.7 log10. All vaccinated mice demon-
strated strong seroconversion, as determined by these
significant antibody titers.
IGF-1 plasma levels
IGF-1 levels were determined by a commercial ELISA
assay specifically designed for the rat/mouse model.
Treatment group mean IGF-1 values were: 304.2 ng/mL

































Figure 1 Determination of the effects of vaccination on mean body weight.
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trols). Statistical analyses either by parametric or non
parametric (one-tailed Mann Whitney) methods did not
indicate a statistically significant differences between any
two treatment groups.
Insulin plasma levels
Insulin levels were determined by a commercial ELISA
assay specifically designed for the mouse model. Treat-
ment group mean insulin values were: 1.552 ng/mL
(JH17), 1.508 ng/mL (JH18) and 1.468 ng/mL (PBS con-
trols). Statistical analyses either by parametric or non -
































Figure 2 Determination of the effects of vaccination on percent
of baseline body weight.indicate a statistically significant differences between any
two treatment groups. Based upon these results, vaccin-
ation did not inhibit insulin secretion, as compared to
normal Insulin levels in PBS controls.
Effect of vaccination on tested parameters
Data in Table 1 summarizes the parameters of baseline
weight, food consumption, chimeric-somatostatin anti-
bodies responses and IGF-1 levels in all mouse treatment
groups. Table 2 summarizes the levels of insulin in mouse
plasma post- second vaccination.
Discussion
The use of therapeutic vaccines in medicine is already

































































Figure 4 Antibody titers to chimeric-somatostatin in plasma.
Table 2 Plasma Insulin levels for mouse treatment groups
at study end
Treatments Insulin, ng/mL SEM Passed normality
test
JH 17 1.552* 0.226 Yes
JH 18 1.508* 0.187 Yes
PBS controls 1.468 0.281 No
* P> 0.05 versus PBS controls.
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other vaccines for treating various pathological condi-
tions and metabolic diseases [15]. A therapy to treat
and manage human obesity by vaccination would af-
ford physicians with a common and accepted medical
procedure to treat a globally widespread human dis-
ease condition. This therapy can be accomplished
without drugs or surgical procedures.
Our approach in designing a therapeutic vaccine target-
ing the counter-regulatory hormone somatostatin is based
on the highly antigenic carrier protein chloramphenicol-
acetyl transferase (CAT) which has been made inactive by
double site mutations [13,16]. Coupled with the enhanced
antigenicity of the chimeric-somatostatin, adjuvants have
been added which contain metabolizable oils, a polyacrylic
polymer and vegetable polysaccharides [14]. These vaccines
have been previously tested in normal, non-obese mice for
safety and efficacy. The JH17 and JH 18 adjuvants were
demonstrated to be safe via intraperitoneal injection in a
0.5 mL dose. The chimeric-somatostatin protein was
demonstrated to be highly antigenic by measuring mouse
weight gain over a 7 day period and demonstrating a 110%
to 130% weight increase compared pre-vaccination weights





JH 17 107.1*** 105.2 0.99
JH 18 104.0*** 96.6 0.99
PBS controls 115.5 113.8 0.98
*** P< 0.0001 versus PBS controls. R2 and slope were determined by linear regressiThe use of somatostatin vaccines for treatment of
obesity is based upon previous studies using GH therapy
[5,6] and the accepted endocrine model of somatostatin
to down-regulate growth hormone releasing hormone
(GHRH), GH and IGF-1 [17]. By reversing the effects of
somatostatin by immuno- regulation, increased levels of
GHRH, GH and IGF-1 were anticipated with increased
metabolism.
The DIO mouse model was chosen as it is easily adapt-
able for vaccination studies and is well characterized for
obesity treatments. Since the effective dose in the C57BL/
6 J male mouse was not previous determined, we utilized
the same dose as we had proven effect in non-obese mice
(1 mg protein/mL in a 0.5 mL dose). In this study, this dose
volume would represent approximately 1.6% of the mouse
body weight. This dose volume would translate to 1.6 liters
of vaccine for a 100 kg human, if volume were the deter-
mining factor of the vaccine’s effectiveness. In a recently
completed pig study, a 1 mL dose containing 0.5 mg of vac-
cine antigen demonstrated effectiveness in 91 kg pigs as
assessed by positive seroconversion and enhanced IGF-1
levels (unpublished data). Therefore, the vaccine’s effective-
ness appears to be more related to immunogen content ra-
ther than the volume of the injection. This specific antigen
dose relationship was previously described by Lunin [18].
Mice were vaccinated and observed for physiological
responses to vaccination with the somatostatin vaccines,
presented as weight loss and reduction in body weight gain.
The amount of food intake was also monitored as it was
important to determine if any continued weight loss was
due to lack of eating the 60% Kcal diet. Although there was
an initial reduction in food consumption during the first
2 days post-1st vaccination, JH17 and JH 18 mice food in-
take was not statistically significant from the food con-





2.987± 0.1225 4.7 *** 304.2
2.849± 0.1301 4.6 *** 440.4
3.038± 0.2002 2 .0 365.6

















Figure 5 Plasma levels of IGF-1 (ng/mL) of treatment
group mice.
Haffer Journal of Animal Science and Biotechnology 2012, 3:21 Page 6 of 7
http://www.jasbsci.com/content/3/1/21Previous experience with the chimeric-somatostatin
vaccines indicated antibody responses are first demon-
strable at 4 to 10 days post-vaccination (IgM and IgG
subclasses). At these time periods, specific antibody
binds to somatostatin and attenuates, but do not com-
pletely eliminate the counter-inhibitory effects of the
hormone. The main increase of GH and IGF-1 follows
this initial antibody production and expected metabolic
changes are observed [13]. Since the biological activity
of the anti-somatostatin antibodies are short-lived, and
are not re-stimulated by endogenous somatostatin, the
vaccine effectiveness is similar to repeated drug adminis-
tration and is not cumulative.
Memory cells responses, as are normally observed with
infectious disease vaccines, have not been observed with
the chimeric-somatostatin vaccines and each vaccination
is likened to a primary dose [18]. Based on these inher-
ent immunological traits of the vaccine, the 2nd vaccin-
ation with either JH 17 or JH 18, did not produce a
memory response, but rather effected a lesser control on
weight gain. In response to the lessened effect, the
vaccine-treated mice continued to gain less weight, while
consuming the same amount of food as the PBS con-
trols. The second vaccination of 1/5th the amount of
protein of the 1st vaccination, can be viewed as a main-
tenance dose.
Reduction in weight gain can be linked to high anti-
somatostatin antibody levels and enhanced IGF-1 quan-
tities in the plasma. Since the samplings of these two
markers were conducted at the end of the study, their
maximal effectiveness would be anticipated to be during
the first week post-vaccination. The demonstration of
high levels of anti-somatostatin antibodies at day 39 is
indicative of the continued presence of down regulation
of somatostatin which is demonstrated by the continuedweight gain differentials observed through the study.
The antibody titers measured at this one time point, are
residual titers and represent the downward part of the
antibody effectiveness curve. A similar argument can be
made for IGF-1 levels in plasma. It could be postulated
the maximal IGF-1 would be seen in the first week fol-
lowing vaccination or revaccination. Even in the pres-
ence of these elevated anti-somatostatin antibodies,
plasma insulin levels in vaccinated mice were similar to
control mice, and demonstrated no statistically signifi-
cant differences.
The two adjuvants reported in this study were
chosen for usefulness in human vaccines. Another ad-
juvant, approved for use in livestock and containing
mineral oil, was also tested in the DIO mouse model
(data not shown). The latter adjuvant produced a
much more heightened weight loss result accompan-
ied by dehydration, lethargy and death in 8/10 mice
treated. Based upon the comparison of these vaccines,
it was determined that the chimeric-somatostatin vac-
cine effects are related to both antigen dose and adju-
vant type.
The differences between the JH17 and JH18 adjuvants
reside only in their plant polysaccharide content, traga-
canthin and arabinogalactan. The results obtained in this
study were not statistically significant in any tested par-
ameter between the two vaccine groups. Comparing the
two adjuvants, the observation of JH18 producing per-
cent of baseline body weight and enhanced IGF-1 are in-
dicative but not predictive of a superior adjuvant effect
of the two polysaccharide additions. In future studies,
only a single adjuvant will be utilized and sham vacci-
nated controls will receive the same adjuvant, but with-
out the chimeric protein included. In this design, the
observable food reduction for 2 days after the 1st vaccin-
ation can be determined to be a property of the adjuvant
or the total vaccine compound.
In summary, DIO mice treated with 2 vaccine formula-
tions, containing the same dose of chimeric-somatostatin
protein, were effective in reducing weight gain and redu-
cing final body weight percentage versus baseline
weights, when compared to PBS control mice. The vac-
cine effect was observable even while the mice were con-
tinuously fed a 60% Kcal fat diet. The vaccination effects
did not significantly reduce cumulative food consump-
tion and was confirmed by residual anti-somatostatin
antibodies in mouse plasma at the study’s end. Mea-
sured levels of Insulin in vaccinates were similar to
controls, further adding to the vaccine’s safety profile.
The final result of the study is the demonstration of
the usefulness of treating obesity with vaccination and
warrants additional studies and parameter monitoring
in other animal models (normal pigs, obese minipigs
and obese dogs).
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